journal
MENU ▼
Read by QxMD icon Read
search

New England Journal of Medicine

journal
https://read.qxmd.com/read/31291511/early-effects-of-an-accountable-care-organization-model-for-underserved-areas
#1
Matthew J Trombley, Betty Fout, Sasha Brodsky, J Michael McWilliams, David J Nyweide, Brant Morefield
BACKGROUND: The Centers for Medicare and Medicaid Services (CMS) developed the Accountable Care Organization (ACO) Investment Model (AIM) to encourage the growth of Medicare Shared Savings Program (MSSP) ACOs in rural and underserved areas. AIM provides financial support to eligible MSSP ACOs by means of prepayment of shared savings. Estimation of the performance of AIM ACOs on measures of spending and utilization in their first performance year would be useful for understanding the viability of ACOs located in these areas...
July 10, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31184814/-unknown-title
#2
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
July 10, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31184813/-unknown-title
#3
(no author information available yet)
No abstract text is available yet for this article.
July 10, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31259488/a-multicenter-trial-of-vena-cava-filters-in-severely-injured-patients
#4
Kwok M Ho, Sudhakar Rao, Stephen Honeybul, Rene Zellweger, Bradley Wibrow, Jeffrey Lipman, Anthony Holley, Alan Kop, Elizabeth Geelhoed, Tomas Corcoran, Philip Misur, Cyrus Edibam, Ross I Baker, Jenny Chamberlain, Claire Forsdyke, Frederick B Rogers
BACKGROUND: Whether early placement of an inferior vena cava filter reduces the risk of pulmonary embolism or death in severely injured patients who have a contraindication to prophylactic anticoagulation is not known. METHODS: In this multicenter, randomized, controlled trial, we assigned 240 severely injured patients (Injury Severity Score >15 [scores range from 0 to 75, with higher scores indicating more severe injury]) who had a contraindication to anticoagulant agents to have a vena cava filter placed within the first 72 hours after admission for the injury or to have no filter placed...
July 7, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31242358/mass-drug-administration-for-scabies-2-years-of-follow-up
#5
LETTER
Lucia Romani, Margot J Whitfeld, Josefa Koroivueta, Mike Kama, Handan Wand, Lisi Tikoduadua, Meciusela Tuicakau, Aminiasi Koroi, Ross M Andrews, John M Kaldor, Andrew C Steer
New England Journal of Medicine, Volume 381, Issue 2, Page 186-187, July 2019.
June 26, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31242357/time-to-reevaluate-u-s-mifepristone-restrictions
#6
Jane E Henney, Helene D Gayle
No abstract text is available yet for this article.
June 26, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31216419/medicaid-work-requirements-results-from-the-first-year-in-arkansas
#7
Benjamin D Sommers, Anna L Goldman, Robert J Blendon, E John Orav, Arnold M Epstein
No abstract text is available yet for this article.
June 19, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31216418/abortion-rights-in-peril-what-clinicians-need-to-know
#8
Elizabeth Nash
No abstract text is available yet for this article.
June 19, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31216396/sustainable-discovery-and-development-of-antibiotics-is-a-nonprofit-approach-the-future
#9
Travis B Nielsen, Eric P Brass, David N Gilbert, John G Bartlett, Brad Spellberg
No abstract text is available yet for this article.
June 19, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31199090/a-phase-3-randomized-trial-of-voxelotor-in-sickle-cell-disease
#10
Elliott Vichinsky, Carolyn C Hoppe, Kenneth I Ataga, Russell E Ware, Videlis Nduba, Amal El-Beshlawy, Hoda Hassab, Maureen M Achebe, Salam Alkindi, R Clark Brown, David L Diuguid, Paul Telfer, Dimitris A Tsitsikas, Ashraf Elghandour, Victor R Gordeuk, Julie Kanter, Miguel R Abboud, Joshua Lehrer-Graiwer, Margaret Tonda, Allison Intondi, Barbara Tong, Jo Howard
BACKGROUND: Deoxygenated sickle hemoglobin (HbS) polymerization drives the pathophysiology of sickle cell disease. Therefore, direct inhibition of HbS polymerization has potential to favorably modify disease outcomes. Voxelotor is an HbS polymerization inhibitor. METHODS: In a multicenter, phase 3, double-blind, randomized, placebo-controlled trial, we compared the efficacy and safety of two dose levels of voxelotor (1500 mg and 900 mg, administered orally once daily) with placebo in persons with sickle cell disease...
June 14, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31199089/a-targeted-agent-for-sickle-cell-disease-changing-the-protein-but-not-the-gene
#11
EDITORIAL
Alexis Thompson
No abstract text is available yet for this article.
June 14, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31189033/the-opportunity-of-cbd-reforming-the-law
#12
Pieter A Cohen, Joshua Sharfstein
No abstract text is available yet for this article.
June 12, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31185157/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes
#13
Mansoor Husain, Andreas L Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G Eliaschewitz, Denise R Franco, Ole K Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D Pedersen, Cees J Tack, Mette Thomsen, Tina Vilsbøll, Mark L Warren, Stephen C Bain
BACKGROUND: Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide. METHODS: We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular risk (age of ≥50 years with established cardiovascular or chronic kidney disease, or age of ≥60 years with cardiovascular risk factors only)...
June 11, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31180194/an-anti-cd3-antibody-teplizumab-in-relatives-at-risk-for-type-1-diabetes
#14
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley, Jennifer B Marks, Wayne Moore, Antoinette Moran, Henry Rodriguez, William E Russell, Desmond Schatz, Jay S Skyler, Eva Tsalikian, Diane K Wherrett, Anette-Gabriele Ziegler, Carla J Greenbaum
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease...
June 9, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31180193/traveling-down-the-long-road-to-type-1-diabetes-mellitus-prevention
#15
EDITORIAL
Clifford J Rosen, Julie R Ingelfinger
No abstract text is available yet for this article.
June 9, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31173679/vitamin-d-supplementation-and-prevention-of-type-2-diabetes
#16
Anastassios G Pittas, Bess Dawson-Hughes, Patricia Sheehan, James H Ware, William C Knowler, Vanita R Aroda, Irwin Brodsky, Lisa Ceglia, Chhavi Chadha, Ranee Chatterjee, Cyrus Desouza, Rowena Dolor, John Foreyt, Paul Fuss, Adline Ghazi, Daniel S Hsia, Karen C Johnson, Sangeeta R Kashyap, Sun Kim, Erin S LeBlanc, Michael R Lewis, Emilia Liao, Lisa M Neff, Jason Nelson, Patrick O'Neil, Jean Park, Anne Peters, Lawrence S Phillips, Richard Pratley, Philip Raskin, Neda Rasouli, David Robbins, Clifford Rosen, Ellen M Vickery, Myrlene Staten
BACKGROUND: Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the risk of diabetes is unknown. METHODS: We randomly assigned adults who met at least two of three glycemic criteria for prediabetes (fasting plasma glucose level, 100 to 125 mg per deciliter; plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5...
June 7, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31173678/d2d-no-defense-against-diabetes
#17
EDITORIAL
Deborah J Wexler
No abstract text is available yet for this article.
June 7, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31167046/mandatory-measles-vaccination-in-new-york-city-reflections-on-a-bold-experiment
#18
Julie D Cantor
New England Journal of Medicine, Volume 381, Issue 2, Page 101-103, July 2019.
June 5, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31166680/five-year-outcomes-with-dabrafenib-plus-trametinib-in-metastatic-melanoma
#19
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalá, John B A G Haanen, Celeste Lebbé, Andrzej Mackiewicz, Piotr Rutkowski, Paul D Nathan, Antoni Ribas, Michael A Davies, Keith T Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V Long
BACKGROUND: Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year survival rates and clinical characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors...
June 4, 2019: New England Journal of Medicine
https://read.qxmd.com/read/31166679/overall-survival-with-ribociclib-plus-endocrine-therapy-in-breast-cancer
#20
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fabio Franke, Louis Chow, Joohyuk Sohn, Keun-Seok Lee, Saul Campos-Gomez, Rafael Villanueva-Vazquez, Kyung-Hae Jung, Arunava Chakravartty, Gareth Hughes, Ioannis Gounaris, Karen Rodriguez-Lorenc, Tetiana Taran, Sara Hurvitz, Debu Tripathy
BACKGROUND: An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Here we report the results of a protocol-specified interim analysis of the key secondary end point of overall survival...
June 4, 2019: New England Journal of Medicine
journal
journal
20199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"